相关临床试验
0
0 进行中
药物批准
67
批准总数
监管机构
1
监管机构数
成立时间
1850
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Kenya's Pharmacy and Poisons Board received an application to register Eli Lilly's Mounjaro on May 7, 2026, and it is at the screening stage. - Aspen Pharmacare submitted the filing under an agreement with Eli Lilly to distribute and promote the tirzepatide drug across sub-Saharan Africa. - Aspen has also filed in Nigeria and expects Mounjaro sales in Africa to exceed $124 million in the financial year ending June 2027.
- Aspen's distribution of Eli Lilly's Mounjaro in South Africa generated roughly R1.5 billion in sales, accounting for about 40% of growth in the country's private pharmaceutical market over the past year. - CEO Stephen Saad said GLP-1 medicines have the potential to become Aspen's biggest product category, with plans to expand Mounjaro into Nigeria, Kenya, and other African markets. - Aspen received Canadian regulatory approval in July for generic injectable semaglutide and expects first sales in the 2027 financial year, pending active ingredient supply from Dr. Reddy's Laboratories. - Saad expects generic GLP-1 medicines globally to cost at least 50% less than branded options, potentially widening access to obesity and diabetes treatments.
- Aspen Pharmacare expects regulatory approval for its unbranded semaglutide version in Canada between May and September 2024, according to CEO Stephen Saad. - The South African pharmaceutical company aims to be among the first to offer generic competition for Novo Nordisk's Ozempic in the Canadian diabetes market. - The generic entry follows the expiration of Novo Nordisk's semaglutide patent for diabetes treatment in January 2024, opening the market to competitors. - Aspen is currently receiving feedback from Canadian regulators regarding its registration application for the diabetes medication.
